Federated Hermes’s Carisma Therapeutics CARM Stock Holding History

Federated Hermes’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,629	Closed	-$1.75K	–	2076
2025 Q1	$1.75K	Buy	5,629 +656	+13%	+$291	﹤0.01%	1960
2024 Q4	$2.08K	Hold	4,973	–	–	﹤0.01%	1970
2024 Q3	$4.88K	Buy	4,973 +1,661	+50%	+$1.8K	﹤0.01%	1860
2024 Q2	$5.03K	Buy	+3,312	New	+$4.94K	﹤0.01%	1838
2021 Q4	–	Sell	-15,945	Closed	-$253K	–	2210
2021 Q3	$253K	Buy	15,945 +12,522	+366%	+$601K	﹤0.01%	1625
2021 Q2	$316K	Buy	+3,423	New	+$218K	﹤0.01%	1604
2018 Q3	–	Sell	-55	Closed	-$2K	–	2261
2018 Q2	$2K	Buy	+55	New	+$2.42K	﹤0.01%	2098
2016 Q1	–	Sell	-38,750	Closed	-$2.33M	–	2105
2015 Q4	$2.33M	Hold	38,750	–	–	0.01%	803
2015 Q3	$1.87M	Buy	+38,750	New	+$2.39M	0.01%	878

Other funds holding CARM

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Federated Hermes's CARM Position: Q2 2025 in Review

Federated Hermes sold out of Carisma Therapeutics (CARM) in Q2 2025, closing a stake of 5,629 shares — an estimated $1.75K sold.

Federated Hermes first reported a position in CARM in Q3 2015 and held it in 9 quarters. The position peaked at $2.33M in Q4 2015. 36 funds tracked by Wall St. Rank hold CARM as of Q2 2025.

Federated Hermes reported no remaining Carisma Therapeutics position as of Q2 2025 after selling out during the quarter.
Federated Hermes sold 5,629 Carisma Therapeutics shares in Q2 2025, an estimated $1.75K.
Federated Hermes first reported a position in Carisma Therapeutics in Q3 2015 and held it in 9 quarters.
Federated Hermes's Carisma Therapeutics position peaked at $2.33M in Q4 2015.
36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.